Boardroom Alpha
Start trial
10-K primary document
APVO · Annual Report (Form 10-K) · Filed March 26, 2026

Aptevo Therapeutics Inc — 10-K exhibit

apvo-ex23_1.htm
Aptevo Therapeutics Inc on Boardroom Alpha
EX-23.1

 

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the following Registration Statements of Aptevo Therapeutics Inc. (the “Company”) of our report dated March 26, 2026, relating to the consolidated financial statements of the Company (which report expresses an unqualified opinion and includes an explanatory paragraph relating to going concern uncertainty), appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2025.

 

•
Registration Statement on Form S-8 (No. 333-265468) pertaining to the 2018 Stock Incentive Plan (as Amended and Restated) of Aptevo Therapeutics Inc.,
•
Registration Statement on Form S-8 (No. 333-213108) pertaining to the Converted Equity Awards Incentive Plan and 2016 Stock Incentive Plan of Aptevo Therapeutics Inc.,
•
Registration Statement on Form S-8 (No. 333-219875) pertaining to the 2016 Stock Incentive Plan of Aptevo Therapeutics Inc.,
•
Registration Statement on Form S-8 (No. 333-226717) pertaining to the 2018 Stock Incentive Plan of Aptevo Therapeutics Inc.,
•
Registration Statement on Form S-8 (No. 333-280789) pertaining to the Second Amended and Restated 2018 Stock Incentive Plan of Aptevo Therapeutics Inc.,
•
Registration Statement on Form S-1 (No. 333- 273067) pertaining to the sale of common stock, prefunded warrants, and common warrants,
•
Registration Statement on Form S-1 (No. 333-278103) pertaining to the sale of common stock, prefunded warrants, and common warrants,
•
Registration Statement on Form S-1 (No. 333-280226) pertaining to the sale of common stock, prefunded warrants, and common warrants
•
Registration Statement on Form S-1 (No. 333-281892) pertaining to the sale of common stock, prefunded warrants, and common warrants,
•
Registration Statement on Form S-1 (No. 333-287244) pertaining to the sale of common stock,
•
Registration Statement on Form S-1 (No. 333-288061) pertaining to the sale of common stock, prefunded warrants, and common warrants,
•
Registration Statement on Form S-1 (No. 333-288134) pertaining to the sale of common stock, prefunded warrants, and common warrants,
•
Registration Statement on Form S-1 (No. 333-288959) pertaining to the sale of common stock,
•
Registration Statement on Form S-1 (No. 333-290663) pertaining to the sale of common stock,
•
Registration Statement on Form S-1 (No. 333-293010) pertaining to the sale of common stock,
•
Registration Statement on Form S-3 (No. 333-275710),

 

 

•
Registration Statement on Form S-3 (No. 333-283983), and
•
Registration Statement on Form S-3 (No. 333-284969).

 

 

/s/ Baker Tilly US, LLP

 

Seattle, Washington

March 26, 2026

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer